Two Deals Beef Up AstraZeneca’s Cancer, Rare Disease Groups
AstraZeneca has strengthened its oncology and rare disease portfolios with two buy-outs totaling close to $3.5 billion, the company has reported.
Source: Drug Industry Daily
AstraZeneca has strengthened its oncology and rare disease portfolios with two buy-outs totaling close to $3.5 billion, the company has reported.
Source: Drug Industry Daily